Veloxis Pharmaceuticals is a biopharmaceutical company, which identifies, develops, and commercializes products that are used in transplantation and adjacent therapies. The Company's patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis's lead product candidate is Envarsus XR, a once-daily dosage tablet version of tacrolimus, which is used to aid in the prophylaxis of organ rejection in transplant recipients.